Although the study was terminated prematurely due to limited activity observed, the study observed a benefit from inhibiting AKT for a patient with NPC possessing PIK3CA gene amplification as the patient with the aforementioned amplification in primary tumor was observed to maintain stable disease condition over 12 months period. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.